A phase I, placebo-controlled, randomised, crossover, bioequivalence trial of sublingual and injectable formulations of apomorphine.

Trial Profile

A phase I, placebo-controlled, randomised, crossover, bioequivalence trial of sublingual and injectable formulations of apomorphine.

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Jun 2015

At a glance

  • Drugs Apomorphine (Primary) ; Apomorphine (Primary)
  • Indications Parkinson's disease
  • Focus Pharmacokinetics
  • Most Recent Events

    • 25 Jun 2015 Results presented at the 19th International Congress of Parkinson's Disease and Movement Disorders (MDS), according to a Cynapsus Therapeutics media release.
    • 25 Jun 2015 Results published in a Cynapsus Therapeutics media release.
    • 18 Jun 2015 Results presented at the 19th International Congress of Parkinson's Disease and Movement Disorders.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top